Importantly, CD45− cancer cells are MMR‐negative (Figure S30, Supporting Information), ascertaining that the anti‐MMR Nb‐IMDQ targets CD45+ hematopoietic cells, of which the pro‐tumoral MHC‐IIlow TAMs are the most prominent MMR‐expressors. This evidence concerns the gene PTPRC and cancer.